These shares just sank to 52-week lows


With the market dropping notably lower today, it will come as no surprise to learn that a number of shares have sunk to 52-week lows.

Three that caught my eye are listed below. Is this a buying opportunity?

The Caltex Australia Limited (ASX: CTX) share price has bounced back now, but earlier today hit a 52-week low of $28.44. The fuel retailer has come under pressure in recent months after the ACCC blocked its attempt to acquire petrol stations owned by Woolworths Group Ltd (ASX: WOW). In addition to this, there is now speculation floating around that Puma Energy might be interested in acquiring these petrol stations. Not only would this bring another player into the market to compete with, but I suspect Puma Energy would be unlikely to contract Caltex to continue supplying these petrol stations. This could hurt its future earnings. So while it shares do look reasonably priced now, I would suggest investors stay clear of Caltex until the new owner of these petrol stations is known.

The Ellex Medical Lasers Ltd (ASX: ELX) share price tumbled to a 52-week low of 55.5 cents on Wednesday. Ellex is a medical device company focused on the development, manufacture and sale of lasers and diagnostic equipment for the treatment of eye diseases. It appears as though investors have been thoroughly disappointed by the sudden deterioration in the company’s financial performance. Although Ellex delivered record revenues of $38.2 million in the first half, it posted a net loss after tax of $2.4 million. In the prior corresponding period the company achieved a profit after tax of $1 million. While I think Ellex could be worth considering due to its undemanding valuation and sizeable market opportunity, it may be prudent to wait to see if its financial performance has improved in the second-half.

The Somnomed Limited (ASX: SOM) share price has continued its decline and hit a 52-week low of $2.40 today. This means the sleep treatment company’s shares have now lost over a third of their value since the turn of the year. Like Ellex, Somnomed has been impressing on the top line but not on the bottom line. Last week the company advised that in FY 2018 revenue is expected to grow by a sizeable 32% to 34% year-on-year to $65 million to $66.2 million. However, despite the strong top line growth the company expects to post an EBITDA loss of between $6.6 million and $7.4 million. While its decline this year has brought its shares down to an attractive level, I think there are better and less risky options in the sleep treatment industry for investors to choose from.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Ellex Medical Lasers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.